Quanta Dialysis Technologies will today unveil its SC+ personal haemodialysis system for market launch next year.
Based on clinical experience obtained during Quanta’s extensive pilot studies, which included over 1,100 successful patient treatments at four NHS Trusts across the UK, the Company has optimised SC+ for commercial launch.
In addition to the small, simple-to-use and powerful features that already set SC+ apart from traditional dialysis machines, Quanta is introducing state-of-the-art technology enhancements that include a new user interface featuring a high resolution screen and improved touch functionality, improvements for usability and capabilities to integrate with digital health solutions.
Maddy Warren, Patient Advocate, said:
“The number of patients with CKD requiring dialysis is going to increase in the coming years, and we currently have a system where the majority are not offered a real choice or flexibility around how they dialyse, leaving them with very little control over their treatment. Patients very quickly become institutionalised, with most believing they have no other treatment options and resigning themselves to a lack of freedom and normality. The whole concept of dialysis, being totally dependent on a machine to keep you alive, can be daunting and overwhelming; physicians need to help give kidney patients confidence that they can take ownership of their treatment and in doing so can greatly improve their quality of life.
I am extremely passionate about home dialysis and truly believe it is the best form of treatment for many kidney patients, and that is why I’m so excited by the potential of SC+ as it empowers patients with the freedom and flexibility to take back control.”
D4D Renal Theme Leads Dr Elizabeth Lindley and Dr Sandip Mitra have provided long-term support to Quanta during the development of their technology, and are members of the company’s Medical Advisory Board.
You can read the full press release on Quanta’s website, here.